Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial

Background: This randomized, open-label trial aimed to compare the efficacy of 10-day bismuth-containing quadruple therapy (BQT) with 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT) as an empirical first-line Helicobacter pylori therapy. Methods: Participants with H. pylori infection were randomly assigned to either 10-day BQT (daily doses of bismuth 300 mg, four times; lansoprazole 30 mg, twice; metronidazole 500 mg, three times; and tetracycline 500 mg, four times) or 7-day STT (lansoprazole 30 mg; amoxicillin 1,000 mg; and clarithromycin 500 mg; each given twice daily). Participants who failed initial therapy were crossed over to the alternative treatment regimen. Primary outcome was the eradication rates of first-line treatment by intention-to-treat analysis. Results: Study participants (n=352) were randomized to receive either 10-day BQT (n=175) or 7-day STT (n=177). The BQT-group achieved a significantly higher eradication rate than the STT-group in the intention-to-treat analysis (74.3% vs 57.1%, respectively; P=0.001), modified intention-to-analysis (87.2% [130/149] vs 68.7% [101/147], respectively; P<0.001) and per-protocol analysis (92.9% [105/113] vs 70.1% [94/134], respectively; P<0.001). Although there was no serious adverse event, the compliance was lower with BQT than STT as a higher proportion of participants in the BQT-group discontinued therapy because of adverse events than those in the STT-group (23.1% vs 9.1%, respectively; P=0.001) Conclusions: Ten-day BQT had higher eradication rates compared to that of the 7-day STT as an empirical first-line treatment for H. pylori eradication in Korea.

Automated summary

The study demonstrated that 10-day bismuth-containing quadruple therapy had higher eradication rates compared to 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy as an empirical first-line treatment for Helicobacter pylori eradication in Korea. Despite the higher eradication rates in the BQT group, compliance was lower, with a higher proportion of participants discontinuing therapy due to adverse events.